Over the years, Ally Bridge Group has invested through the following strategies: 1) venture; 2) private equity, including buyout and growth capital; 3) public equity.
- Venture – investing in innovative life science companies at early to developmental stages primarily in the US, both private and public, focused on innovative drugs, medical devices and diagnostics.
- Buyout and large growth capital – investing in cashflow-generating life science companies in China, Europe and the US. We leverage our unique strengths in capital markets, M&A and global cross-border investing, deal-making, execution, and enabling of cross-border business development & partnerships.
- Public equity – employing fundamental and bottom-up research-driven, with a proactive value-add approach to investing in public equities from Asia to the US.
Today and going forward, Ally Bridge Group primarily focuses on leading high-impact investments in later-stage cutting-edge life science innovations in the U.S. across the medtech, tools and diagnostics, biopharmaceutics and, increasingly, digital health/telemedicine sectors – in both the private and public markets in an integrated fashion.